Any content you receive is for information purposes only. Always conduct your own research.*Disseminated on Behalf of Medicus Pharma Ltd.
Jeff Ackerman Puts (MDCX) Back On This Morning's Watchlist—Wednesday, December 24, 2025
Full Coverage Starts In The Morning
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Take A Look At (MDCX) While It's Still Early…
December 24, 2025
Momentum Watch | See Why (MDCX) is Lighting Up Our Radar Right Now Dear Reader, Please tell me you have (MDCX) on your screen right now. It's lighting up our screen as we speak. TradingView's technical analysis dashboard is flashing multiple bullish signals on (MDCX), putting it back in the spotlight as momentum builds. When a profile starts stacking bullish confirmations across key indicators, it often signals that something is shifting beneath the surface—and (MDCX) is doing exactly that right now. If you missed my earlier email, keep reading for a quick breakdown on what could be triggering these signals and why this move has the potential to start pulling attention fast. ==== Artificial intelligence just entered the conversation in a meaningful way—and it's not happening in a vacuum. This week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced a new initiative to deploy AI-driven clinical data analytics across its development pipeline, beginning with its late-stage Teverelix program. The goal: sharper trial execution, smarter site selection, improved patient stratification, and more efficient use of clinical resources as programs advance. That AI update didn't arrive alone. Just days earlier, the company confirmed full enrollment of all 90 patients in its U.S. Phase 2 SkinJect study—clearing a major clinical milestone and setting the stage for topline results expected in Q1 2026. Momentum, timing, fresh potential catalysts… all hitting at once. That's exactly what's unfolding right now with Medicus Pharma Ltd. (NASDAQ: MDCX). We've covered this profile before, but the latest sequence of developments has pushed it right back onto our radar heading into Wednesday morning, December 24, 2025—and the timing couldn't be more interesting. But keep in mind, (MDCX) is working with an ultra-thin float of under 8M shares according to MarketWatch. When companies have small floats like this, the potential exists for big moves if demand begins to shift. Earlier this month, (MDCX) made an approximate 34% move in under 24 hours, between December 3 and December 4. Add in insider ownership north of 30%—the kind of alignment that often signals confidence behind the scenes—and you can see why momentum watchers are paying attention again. All signs point to a setup worth a closer look. Analyst Targets Suggests Over 1,700% Upside Potential
From Recent Range… Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting over 1,700% upside potential from its recent $1.50 range. That's not the only target now in play. Brookline Capital's Kumaraguru Raja recently raised his target from $12 to $20, while Maxim Group's Jason McCarthy reiterated a $20 target in a report published a few days ago—reflecting continued confidence and over 1,200% upside potential from current levels. Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs. With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning's session. FDA Clears Streamlined Path for SkinJect's Next Phase
Medicus Pharma Ltd. (NASDAQ: MDCX) received positive Type C meeting feedback from the U.S. FDA for its SkinJect program—a dissolvable microneedle patch being developed to non-invasively treat basal cell carcinoma (BCC). The agency confirmed that the program may follow the streamlined 505(b)(2) pathway, potentially reducing both cost and development time, and also offered guidance on study design, endpoints, and formulation improvements, including an adhesive layer and applicator system. (MDCX) is advancing two Phase 2 trials: SKNJCT-003 in the U.S., now over 75% enrolled following a strong interim readout, and SKNJCT-004 across six clinical sites abroad. Enrollment for SKNJCT-003 is expected to complete before the end of Q4 2025, with an End-of-Phase-2 FDA meeting targeted for Q1 2026. The company estimates the market for non-invasive BCC treatments could approach $2B annually. Executive Chairman and CEO Dr. Raza Bokhari noted that the FDA's feedback "marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC," reinforcing growing confidence as development advances. (MDCX) Opens New Pathway for Patients With
Compassionate Use Partnership
Medicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA) to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide. The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision. The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development. Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)'s mission to bring targeted innovation to conditions with significant unmet medical needs. First Patient Treated in UAE Marks Key Milestone in
Global Phase 2 Expansion Just this week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC). Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai. The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio. According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone "marks an important step in expanding Medicus's clinical footprint beyond the U.S.," underscoring the company's push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential. (MDCX) Bolsters Clinical Portfolio With Teverelix
—A Dual-Use Phase 2b Candidate Medicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer. The move broadens (MDCX)'s clinical scope into two therapeutic areas with a combined $6B market potential.
Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients. In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies. The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board. Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need. Recent Developments
Dec 22, 2025 – AI-Driven Clinical Analytics Initiative Announced
(MDCX) entered into a non-binding letter of intent with Reliant AI to develop an artificial intelligence–powered clinical data analytics platform designed to support more efficient clinical trial execution. The initial focus will be on the Teverelix program, with applications including dynamic site selection, patient stratification, and enrollment forecasting for studies planned to begin in 2026, while maintaining capital discipline through a milestone-based engagement. Dec 15, 2025 – Phase 2 SkinJect Trial Fully Enrolled
(MDCX) successfully completed enrollment of all 90 patients for its Phase 2 SKNJCT-003 study evaluating SkinJect™ for the non-invasive treatment of basal cell carcinoma. The company expects to release topline results in Q1 2026 and to request an End-of-Phase-2 meeting with the FDA in the first half of 2026. Dec 01, 2025 – Appointment of Carolyn Bonner as Chief Financial Officer
(MDCX) promoted its President, Carolyn Bonner, to Chief Financial Officer, strengthening its executive leadership as the company scales its clinical, regulatory, and future commercial operations. Her expanded role is expected to support Medicus through its next phase of growth. Nov 24, 2025 – Company Highlights Expanded Innovation Across Skin and Prostate Cancer Programs
(MDCX) released an in-depth update showcasing the strategic value of both its SkinJect D-MNA platform for BCC and its late-stage Teverelix program addressing high-need prostate cancer and acute urinary retention. The company emphasized its multi-market pipeline expansion and growing clinical footprint. Nov 17, 2025 – FDA CNPV Application Filed for SkinJect (SKNJCT-003)
(MDCX) submitted its Commissioner's National Priority Voucher (CNPV) application for SkinJect, positioning the program for a potential 1–2 month FDA review instead of the standard 10–12 months. The application highlights SkinJect's alignment with national priorities such as affordability, access, domestic manufacturing, public-health impact, and rare-disease relevance, including Gorlin Syndrome. Nov 14, 2025 – Q3 2025 Corporate Update & Financial Highlights
(MDCX) reported continued progress across its SkinJect and Teverelix programs, expanded trial activity in the U.S., U.K., and UAE, and strengthened patient-access initiatives through the Gorlin Syndrome Alliance. The company also improved its balance sheet with $10.4M in new capital and reaffirmed confidence in its growing global clinical footprint. 9 Reasons Why (MDCX) Is Topping Our Watchlist This
Morning—Wednesday, December 24, 2025
1. Analyst Coverage: multiple firms have issued targets at $20 and as high as $27, framing expectations for (MDCX) that suggest roughly 1,200% to 1,700% upside potential from its recent range. 2. AI Integration: recent plans to deploy AI-driven clinical analytics place (MDCX) among a small group of companies applying advanced data intelligence to improve trial execution and efficiency.
3. Limited Float: with fewer than 8M shares available, (MDCX)'s small float has the potential for big moves if demand begins to shift. 4. Recent Momentum: the chart for (MDCX) showcases an approximate 34% move in under 24 hours last week. 5. Insider Confidence: leadership continues to hold more than 35% of (MDCX)'s float, reinforcing long-term confidence behind the scenes. 6. Regulatory Boost: recent FDA Type C feedback has given (MDCX)'s SkinJect program a clearer and potentially faster 505(b)(2) route. 7. Global Progress: new clinical activity across U.S., U.K., and UAE sites shows (MDCX) expanding its SkinJect program on multiple fronts. 8. Expanded Pipeline: following the Antev acquisition, (MDCX) now holds two late-stage therapeutic programs—SkinJect and Teverelix—each targeting high-need medical conditions. 9. Phase 2 Milestone: full enrollment of 90 patients in the SkinJect Phase 2 study positions (MDCX) ahead of expected topline results targeted for Q1 2026.
All nine factors point to one conclusion—(MDCX) is entering a decisive stretch. With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar. Take A Look At (MDCX) While It's Still Early…
With all of these forces stacking at once, (MDCX) sits in a rare position—one shaped by a float under 8M shares, a chart that has already produced multiple sharp overnight moves, and analyst targets stretching as high as $27 from its recent $1.50 range, which suggest over 1,200% to 1,700% upside potential.
Add in leadership holding more than a third of the float, fresh FDA alignment on a streamlined regulatory path, expanding Phase 2 activity across three regions, and a broadened pipeline now anchored by two late-stage programs… and it becomes clear why this name refuses to drift quietly into the background. We have all eyes on (MDCX) this morning. Take a look at (MDCX) while it's still early. Also, keep a lookout for my next update, it could be hitting any moment. Sincerely, Jeff Ackerman
Managing Editor Stock News Trends
| 
0 Response to "Momentum Watch: See Why (MDCX) is Lighting Up Our Radar Right Now"
Post a Comment